Drugs / RV001V
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03199872 | Mar 2017 → Aug 2018 | prostate cancer | RhoVac APS | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04114825 | Nov 2019 → Apr 2022 overdue | prostate cancer | RhoVac APS | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RV001V | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04114825 ↗ |
| Modality | Vaccine | “synthetic long peptide vaccine targeting Ras homolog gene family member C (RhoC)” PMID 33184050 ↗ Nov 2020 |
| Route | Subcutaneous | “received subcutaneous injections of 0.1 mg of a single RhoC-derived 20mer peptide” PMID 33184050 ↗ Nov 2020 |
| Target | RHOC | “synthetic long peptide vaccine targeting Ras homolog gene family member C (RhoC)” PMID 33184050 ↗ Nov 2020 |